LTRN Lantern Pharma Inc
Company Analysis
Latest News
🔴 Lantern Pharma is trading 11% down today after announcing a registered direct offering
Lantern Pharma is trading at $0.97, down 10.56%, following its September 29 announcement of a registered direct offering. - The deal covers 3,669,725 shares...
🔴 Lantern Pharma is trading 5.53% down
Lantern Pharma is trading 5.53% down now at $1.02, with no clearly confirmed catalyst identified for the September 30 decline. - The September 29 close was...
🟢 Lantern Pharma is trading 7.8% up in pre-market amid announced offering targeting about $4 million
Lantern Pharma is trading 7.77% up at $1.17 in pre-market on September 30; the offering is the clearest company-specific context, but no direct link was...
🔴 Lantern Pharma is trading 6.9% down in after-hours trading after announcing registered direct offering
Lantern Pharma is trading 6.9% down in after-hours trading at $1.01 after announcing a registered direct offering expected to raise approximately $4 million...
🔴 Lantern Pharma is trading 6.4% down today after announcing a roughly $4 million direct offering
Lantern Pharma is trading at $1.02 (-6.42%) after announcing a registered direct offering expected to raise about $4 million before expenses. - The offering...
🔴 Lantern Pharma is trading 12.31% down in pre-market after announcing a $4 million registered direct offering
Lantern Pharma is trading at $0.96, down 12.31%, after announcing a registered direct offering. - On September 29, 2026, it announced 3,669,725 shares or...
🟢 Lantern Pharma is trading 8.26% up in after-hours trading — no clear company-specific catalyst
Lantern Pharma is trading at $1.18, up 8.26% after hours versus its September 28 regular-session close of $1.09, with no clear company-specific catalyst...
🔴 Lantern Pharma is trading 5.7% down with no confirmed company-specific catalyst
Lantern Pharma is trading 5.7% down at $1.15 on September 28, 2026, with no confirmed company-specific catalyst explaining the decline. - The September 22...
🟢 Lantern Pharma is trading 6.6% up in pre-market; catalyst unclear
Lantern Pharma is trading at $1.30, up 6.56%, with no confirmed catalyst for the September 28 pre-market rise. - No verified Lantern Pharma announcement...
🟢 Lantern Pharma is trading 5.79% up today amid broader market strength
Lantern Pharma is trading 5.79% up at $1.28, primarily in line with broader risk-on market sentiment. - The move follows a September 24 close of $1.21, after...
🟢 Lantern Pharma is trading 7.81% up in after-hours trading as no company-specific catalyst was verified
Lantern Pharma is trading 7.81% higher at $1.30 after hours, with no verified company-specific announcement explaining the rebound. - Shares closed September...
🔴 Lantern Pharma is trading 10.07% down today amid sharper biotech-sector losses
Lantern Pharma is trading at $1.25, down 10.07%, amid biotech-sector weakness. - No new company-specific announcement was identified for September 24, 2026. -...
🔴 Lantern Pharma is trading 5.8% down today amid biotech-sector weakness
Lantern Pharma is trading at $1.31, down 5.76%, as biotechnology stocks fall alongside higher Treasury yields, inflation concerns and weaker broader-market...
🔴 Lantern Pharma is trading 5% down in pre-market as immediate catalyst remains unclear
Lantern Pharma is trading 5.04% lower at $1.32 versus its September 23 close of $1.39; the immediate catalyst is unclear amid weaker U.S. index futures and...
🟢 Lantern Pharma is trading 7.91% up today in pre-market after USPTO allows LP-284 blood-cancer patent
Lantern Pharma is trading at $1.50, up 7.91%, after the USPTO issued a Notice of Allowance for its LP-284 blood-cancer treatment patent. - Allowed claims...
Lantern Pharma Wins a Patent Shield for Its Cancer Drug — But Can a $19 Million Company Afford to Use It?
Shares of Lantern Pharma surged 11.8% to $1.52 Tuesday after the U.S. Patent and Trademark Office gave the green light on a patent covering the company's...
🟢 Lantern Pharma is trading 11.76% up today after USPTO Notice of Allowance for LP-284 patent
Lantern Pharma is trading 11.76% higher at $1.52 after announcing a USPTO Notice of Allowance for an LP-284 treatment patent covering aggressive B-cell...
🟢 Lantern Pharma is trading 6% up today as biotech stocks rise
Lantern Pharma is trading 5.88% up at $1.44, primarily as broader positive biotech-sector sentiment lifts stocks. - The move follows three consecutive...
🟢 Lantern Pharma rises 6.6% — Biotech Sector Surges in Pre-Market on Multiple Positive News Snippets
With Biotech (XBI) up 2.6%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Lantern Pharma is trading 5.67% down today as the specific reason remains unclear
Lantern Pharma is trading 5.67% down at $1.42, continuing the retreat from the September 21, 2026 close of $1.50, while the specific reason remains unclear. -...